Background: A significant number of heart failure (HF) patients with reduced left ventricular ejection fraction (LVEF) experience ventricular function recovery during follow-up. We studied the variables associated with LVEF recovery in patients treated with sacubitril/valsartan (SV) in clinical practice. Methods: We analyzed data from a prospective and multicenter registry including 249 HF outpatients with reduced LVEF who started SV between October 2016 and March 2017. The patients were classified into 2 groups according to LVEF at the end of follow-up (>35%: group R, or ≤35%: group NR). Results: After a mean follow-up of 7 ± 0.1 months, 62 patients (24.8%) had LVEF >35%. They were older (71.3 ± 10.8 vs. 67.5 ± 12.1 years, p = 0.025), and ...
Purpose: Sacubitril/valsartan has been associated with a positive reverse left ventricular remodelli...
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure wi...
BACKGROUND: Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was s...
Background: While disease modifying therapies exist for heart failure (HF) with reduced left ventric...
Background: While disease-modifying therapies exist for heart failure (HF) with reduced left ventric...
Background: Sacubitril/valsartan improves outcome in patients with heart failure (HF) with reduced l...
Background: Sacubitril/valsartan improves outcome in patients with heart failure (HF) with reduced l...
Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortal...
Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortal...
Background: Compared to angiotensin inhibition, angiotensin-neprilysin “blockade” improves mortality...
Objective: Current guidelines recommend an implantable cardiac defibrillator (ICD) in patients with ...
Background: Heart rate recovery (HRR) is a marker of vagal tone, which is a powerful predictor of mo...
Background: Heart rate recovery (HRR) is a marker of vagal tone, which is a powerful predictor of mo...
Abstract Aims Despite well‐established benefits of sacubitril/valsartan for cardiac reverse remodell...
BACKGROUND: Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was s...
Purpose: Sacubitril/valsartan has been associated with a positive reverse left ventricular remodelli...
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure wi...
BACKGROUND: Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was s...
Background: While disease modifying therapies exist for heart failure (HF) with reduced left ventric...
Background: While disease-modifying therapies exist for heart failure (HF) with reduced left ventric...
Background: Sacubitril/valsartan improves outcome in patients with heart failure (HF) with reduced l...
Background: Sacubitril/valsartan improves outcome in patients with heart failure (HF) with reduced l...
Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortal...
Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortal...
Background: Compared to angiotensin inhibition, angiotensin-neprilysin “blockade” improves mortality...
Objective: Current guidelines recommend an implantable cardiac defibrillator (ICD) in patients with ...
Background: Heart rate recovery (HRR) is a marker of vagal tone, which is a powerful predictor of mo...
Background: Heart rate recovery (HRR) is a marker of vagal tone, which is a powerful predictor of mo...
Abstract Aims Despite well‐established benefits of sacubitril/valsartan for cardiac reverse remodell...
BACKGROUND: Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was s...
Purpose: Sacubitril/valsartan has been associated with a positive reverse left ventricular remodelli...
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure wi...
BACKGROUND: Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was s...